SG Americas Securities LLC Increases Stake in Replimune Group, Inc. $REPL

SG Americas Securities LLC grew its position in Replimune Group, Inc. (NASDAQ:REPL) by 868.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 98,731 shares of the company’s stock after buying an additional 88,532 shares during the period. SG Americas Securities LLC owned approximately 0.13% of Replimune Group worth $414,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the last quarter. Raymond James Financial Inc. bought a new position in Replimune Group in the 2nd quarter valued at approximately $69,000. Griffin Asset Management Inc. purchased a new stake in Replimune Group during the 3rd quarter valued at $82,000. Tower Research Capital LLC TRC increased its holdings in shares of Replimune Group by 2,020.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after purchasing an additional 9,235 shares in the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Replimune Group by 99.9% in the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after purchasing an additional 4,925 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $7.71 on Monday. The firm has a 50 day moving average of $9.19 and a 200 day moving average of $7.44. The firm has a market capitalization of $604.77 million, a price-to-earnings ratio of -2.23 and a beta of 0.72. Replimune Group, Inc. has a 12-month low of $2.68 and a 12-month high of $14.80. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on REPL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price for the company in a research report on Monday, October 20th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the company from $3.00 to $13.00 in a report on Monday, October 20th. Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Monday, October 20th. Finally, HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, October 27th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $9.75.

Insider Buying and Selling

In other news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total value of $111,300.00. Following the transaction, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,248 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider owned 139,685 shares of the company’s stock, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 25,625 shares of company stock worth $257,607. Corporate insiders own 5.20% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.